Voyager Therapeutics Current Ratio 2014-2022 | VYGR

Voyager Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Voyager Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.17B $0.10B 1.68
2021-12-31 $0.14B $0.05B 2.68
2021-09-30 $0.13B $0.03B 4.73
2021-06-30 $0.15B $0.03B 6.02
2021-03-31 $0.18B $0.03B 7.10
2020-12-31 $0.20B $0.03B 7.39
2020-09-30 $0.22B $0.04B 5.14
2020-06-30 $0.25B $0.07B 3.65
2020-03-31 $0.27B $0.07B 3.76
2019-12-31 $0.31B $0.08B 4.01
2019-09-30 $0.33B $0.08B 4.09
2019-06-30 $0.34B $0.07B 4.93
2019-03-31 $0.37B $0.06B 6.21
2018-12-31 $0.16B $0.03B 5.13
2018-09-30 $0.18B $0.03B 6.08
2018-06-30 $0.20B $0.03B 6.88
2018-03-31 $0.22B $0.03B 7.13
2017-12-31 $0.17B $0.02B 10.81
2017-09-30 $0.13B $0.02B 6.12
2017-06-30 $0.15B $0.01B 12.23
2017-03-31 $0.16B $0.01B 14.56
2016-12-31 $0.18B $0.01B 12.95
2016-09-30 $0.19B $0.02B 9.96
2016-06-30 $0.21B $0.02B 10.40
2016-03-31 $0.21B $0.02B 8.91
2015-12-31 $0.20B $0.02B 8.19
2015-09-30 $0.11B $0.02B 4.65
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.01B $0.00B 3.38
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.03
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00